Cognitive impairments and breast cancer: A critical review of the literature;Altérations cognitives et cancer du sein: Une revue critique de la littérature

Bulletin du Cancer

Volumn 96, Issue 2, 2009, Pages 239-248

  Vandenbossche, S ^a,b   Fery, P ^a   Razavi, D ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Chemotherapy; Cognitive impairements; Hormone therapy

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DOCETAXEL; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN;

BRAIN DAMAGE; BRAIN DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL EVALUATION; COGNITION; COGNITIVE DEFECT; DISEASE SEVERITY; DISTRESS SYNDROME; FATIGUE; FEMALE; FREQUENCY ANALYSIS; HUMAN; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROTOXICITY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ATTENTION; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; MEMORY DISORDERS;

EID: 66349093082     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0818     Document Type: Review

References (39)

1. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005 ; 59(1) : 60-70. (Pubitemid 41405841)
2. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006 ; 20(1) : 76-89.
3. Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005 ; 12(4) : 279-287
4. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999 ; 85(3) : 640-650 (Pubitemid 29075285)
5. Wieneke MH, Dienst ER. Neuropsychological assesment of cognitive functionning adjuvant treatment following chemotherapy for breast cancer. Psychooncology 1995 ; 4 : 61-66 (Pubitemid 26093776)
6. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998 ; 90(3) : 210-218 (Pubitemid 28114539)
7. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000 ; 18(14) : 2695-2701 (Pubitemid 30463551)
8. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002 ; 20(2) : 485-493 (Pubitemid 34072533)
9. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002 ; 13(9) : 1387-1397
10. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, et al. Cognitive function, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003 ; 21(22) : 4175-4183 (Pubitemid 46606186)
11. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004 ; 26(7) : 955-969 (Pubitemid 39577316)
12. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005 ; 104(11) : 2499-2507 (Pubitemid 41691574)
13. Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006 ; 17(3) : 415-423 (Pubitemid 43329577)
14. Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006 ; 94(6) : 828-834
15. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004 ; 100(11) : 2292-2299 (Pubitemid 38657875)
16. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairement associated with adjuvant therapy in breasy cancer. Psychooncololy 2005 ; 15 : 422-430
17. O'Shaughnessy JA, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005 ; 5(6) : 439-446
18. Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational longitudinal study. Breast 2005 ; 14(2) : 142-150 (Pubitemid 40353042)
19. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006 ; 98(23) : 1742-1745 (Pubitemid 44942713)
20. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 2003 ; 5(2) : 89-95. (Pubitemid 36416837)
21. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC. Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 2006 ; 36(1) : 55-59 (Pubitemid 43210736)
22. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998 ; 279(9) : 688-695 (Pubitemid 28138739)
23. Delozier T. L'hormonothérapie du cancer du sein : la fin du tamoxifène ? Bull Cancer 2005 ; 92 : 142-150
24. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered fronto-cortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10-years after chemotherapy. Breast Cancer Res Treat 2007 ; 103(3) : 303-311 (Pubitemid 46944511)
25. Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double blind chemoprevention trial (IBIS II). Lancet Oncol 2008 ; 9(10) : 953-961
26. Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 2003 ; 86(3-5) : 405-412 (Pubitemid 37412579)
27. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008 ; 19(4) : 623-629
28. Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005 ; 68(Suppl 1) : 3-11. (Pubitemid 40663255)
29. Bender CM, Yasko JM, Kirkwood JM, Ryan C, Dunbar-Jacob J, Zullo T. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res 2000 ; 9(3) : 352-363
30. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005 ; 104(4) : 788-793 (Pubitemid 41113679)
31. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007 ; 7(3) : 192-201. (Pubitemid 46310497)
32. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 2008 ; 18(2) : 121-131
33. Vardy J, Judge K. Acute mountain sickness and ascent rates in trekkers above 2,500 m in the Nepali Himalaya. Aviat Space Environ Med 2006 ; 77(7) : 742-744 (Pubitemid 44061457)
34. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993 ; 11(3) : 570-579 (Pubitemid 23071057)
35. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000 ; 64(2) : 165-176 (Pubitemid 32010334)
36. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007 ; 11(1) : 6-15.
37. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological and neuro-imaging perspectives. Semin Clin Neuropsychiatry 2003 ; 8(4) : 201-216 (Pubitemid 37474731)
38. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007 ; 109(1) : 146-156 (Pubitemid 46120202)
39. Kreukels BP, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, Muller MJ, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer 2006 ; 7(1) : 67-78. (Pubitemid 43862837)